• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Grants Orphan Drug Designation to Thrombotic Thrombocytopenic Purpura Drug

News
Article

GC1126A is designed to treat the rare blood disorder.

GC Biopharma Corp. announced that GC1126A has been granted orphan drug designation by FDA. This will provide certain incentives, such as tax credits for clinical development costs.

The drug is a treatment for Thrombotic Thrombocytopenic Purpura, a rare and life-threatening blood disorder that can cause the formation of small blood clots.

GC1126A is designed to evade antibodies, providing it with a longer half-life within the body.

In a press release, a spokesperson for GC Biopharma said, “We are dedicated to collecting data to develop a Best-in-Class treatment for such rare disorders. We remain committed to our mission of providing patients with new treatment options by continuously developing innovative drugs."

Related Videos
Related Content